GlaxoSmithKline struck deals with Jiangsu Hengrui Pharma to develop up to 12 medicines, including a PDE3/4 inhibitor HRS-9821 for COPD with a $500 million upfront fee and potential $12 billion milestones. Additionally, Novatim partnered with U.S. firm Erigen to co-develop a BCMA/CD19 dual-target CAR-T therapy KQ-2003, expanding rights globally outside Greater China. These alliances reflect significant momentum in Asian biopharma collaborations, promoting advancement of respiratory and oncology therapeutics across global markets.